bluebird bio (bluebird bio) Debt-to-Equity : 1.37 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is bluebird bio Debt-to-Equity?

bluebird bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $71.68 Mil. bluebird bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $232.02 Mil. bluebird bio's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $222.54 Mil. bluebird bio's debt to equity for the quarter that ended in Sep. 2023 was 1.36.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for bluebird bio's Debt-to-Equity or its related term are showing as below:

BLUE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.14 Max: 1.75
Current: 1.37

During the past 12 years, the highest Debt-to-Equity Ratio of bluebird bio was 1.75. The lowest was 0.05. And the median was 0.14.

BLUE's Debt-to-Equity is ranked worse than
91.2% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs BLUE: 1.37

bluebird bio Debt-to-Equity Historical Data

The historical data trend for bluebird bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Debt-to-Equity Chart

bluebird bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.15

0.05

0.24

1.43

bluebird bio Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															1.75	1.43	0.77	1.06	1.37

Competitive Comparison of bluebird bio's Debt-to-Equity

For the Biotechnology subindustry, bluebird bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bluebird bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bluebird bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where bluebird bio's Debt-to-Equity falls into.

bluebird bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

bluebird bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(51.16	+	230.23)	/	196.343
	=	1.43

bluebird bio's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(71.684	+	232.023)	/	222.536
	=	1.36

bluebird bio (NAS:BLUE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

bluebird bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of bluebird bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

bluebird bio (bluebird bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BLUE:Mexico

Address

455 Grand Union Boulevard, Somerville, MA, USA, 02145

Website

https://www.bluebirdbio.com

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Executives

Richard A Colvin	officer: Chief Medical Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Andrew Obenshain	officer: President of SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Christopher Krawtschuk	officer: Chief Financial Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Thomas J Klima	officer: Chief Commercial Officer, SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A. Paulson	director	85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Elisabeth Leiderman	director	1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole	officer: SVP, Secy. & General Counsel	C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann	officer: Chief Regulatory Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman	officer: Chief Financial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten	officer: Chief Accounting Officer	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145